AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Thoracoscopic Surgical Versus Catheter Ablation Approaches for Primary Treatment of Persistent Atrial Fibrillation

RecruitingNAAges 18 Years - 80 YearsAllAcademisch Medisch Centrum - Universiteit van Ams…
💬

In plain words

What the trial is, and whether it could suit you

Rationale: Atrial fibrillation (AF) is a highly prevalent cardiac arrhythmia. AF is classified as paroxysmal or persistent AF, based on the duration and persistency of the arrhythmia. Despite state-of-the-art pharmacological therapies targeting the ventricular rate or aiming to restore sinus rhythm, many patients with persistent AF stay symptomatic. Catheter ablation, endocardial pulmonary vein isolation (PVI) in particular, is the most commonly applied approach to treat drug refractory persistent AF, but particularly in this patient group results are modest. Alternatively, the PVs can be approached epicardially by thoracoscopic surgery to isolate the PVs. This approach is more efficacious, at the cost of a more invasive procedure and longer hospital stay. However, no studies have been conducted comparing catheter with thoracoscopic ablation in patients with persistent AF as a primary in

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: * Age is between 18 and 80 years * Persistent AF as defined following the ESC 2016 Guidelines, evidenced by 1) ongoing AF on the ECG or 2) documentation of AF necessitating cardioversion. * AF documented by ECG or Holter \< 1 year ago. * At least one class I or III anti-arrhythmic drug in standard dosage has failed or is not tolerated. * Left atrial volume index ≤ 45 ml/m2 * Legally competent and willing to sign the informed consent. * Willing and able to adhere to the follow-up visit protocol. * Life expectancy of at least 2 years. Exclusion Criteria: * Prior intervention (catheter ablation or minimally-invasive thoracoscopic ablation) for AF. * AF is secondary to electrolyte imbalance, thyroid disease or other reversible or non-cardiovascular causes. * Documentation of CTI dependent atrial flutter * Valvular AF * Paroxysmal AF * Long standing Persistent AF, defined as AF continuously present for longer than 1 year. * Body mass index \>35kg/m2 * NYHA class IV heart failure symptoms or left ventricular ejection fraction \<35%. * NYHA class III heart failure symptoms, unless caused or aggravated by AF. * Myocardial infarction within the preceding 2 months. * Active infection or sepsis (as evidenced by increased white blood cell count, elevated CRP level or fever \>38,5 °C). * Known and documented carotid stenosis \> 80% * Planned cardiac surgery for other purposes than AF. * Pregnancy or child bearing potential without adequate anticonception. * Requirement of anti-arrhythmic drugs for ventricular arrhythmias. * Presence of intracardiac mass or thrombus (discovery of any thrombus or intracardiac mass after signing of the informed consent will result in withdrawal of the subject from the study) * Co-morbid condition that possesses undue risk of general anesthesia or port access cardiac surgery (in the opinion of the operator). * History of previous radiation therapy on the thorax * Circumstances that prevent follow-up * No vascular access for catheterization. * History of previous thoracotomy. * Factors precluding transseptal puncture for catheterization.
💊

What it tests

  • Thoracoscopic pulmonary vein isolation without additional lesion + left atrial appendage exclusion/amputation
  • Catheter pulmonary vein isolation without additional lesions
📍

Where

3 sites
Amsterdam University Medical Center location AMC
Amsterdam, Netherlands
Maastricht UMC+
Maastricht, Netherlands
St. Antonius Ziekenhuis Nieuwegein
Nieuwegein, Netherlands
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy